Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

KTTA vs BFRI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KTTA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–4 Matrix Metrics)

KTTA Overall Winner 6-Pillar Tally: KTTA 2 – 2 BFRI (2 Tie) Matrix Metrics: KTTA 5 – 4 BFRI

As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over Biofrontera Inc. (BFRI) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas BFRI carries 44.0/100 (HOLD) at $0.53 (13.0x Forward P/E, -12.6% operating margin).

  • Composite vs. Pillar Nuance: While BFRI currently prints a higher short-term Unified Composite Score (44.0/100 HOLD vs. KTTA 42.1/100 HOLD), KTTA captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -12.6% operating margin) and revenue trajectory (+1498.1% vs. +29.8% YoY).
  • Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile BFRI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KTTA vs BFRI
KTTA NASDAQ Head-to-Head Winner
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
TTM Revenue $486,559
Forward P/E N/M
Beta / 30D Vol 0.68β · 185% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.1%) with fading momentum, RSI 50
RSI-14: 49.6 · SMA20: $0.48 · SMA50: $0.47
BFRI NASDAQ
Biofrontera Inc. Common Stock
Pharmaceutical Preparations
$0.53
-7.02% 1D
Market Cap $10.2M
TTM Revenue $48M
Forward P/E 13.0x
Beta / 30D Vol 1.84β · 125% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 25.0 Fund 42.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.2%), weak momentum, RSI 28
RSI-14: 27.5 · SMA20: $0.79 · SMA50: $0.93

6-Pillar Scorecard Institutional Category Breakdown (KTTA 2 – 2 BFRI)

Columns: Metric · KTTA · BFRI
1. Valuation Multiples BFRI
Forward P/E N/M 13.0x
Trailing P/E N/M 13.0x
PEG Ratio N/M N/M
EV / Revenue 36.3x 0.2x
2. Growth & Scale KTTA
Revenue Growth (YoY) +1498.1% +29.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $486,559 $48M
Market Cap $17.7M $10.2M
3. Profitability & Quality KTTA
Gross Margin -0.5% 79.6%
Operating Margin 0.0% -12.6%
Net Profit Margin 0.0% -12.7%
Return on Equity (ROE) -88.8% -988.4%
4. Balance Sheet & Cash Flow BFRI
Cash Generation (TTM) -$18M -$9.3M
Cash Flow Margin N/A -19.3%
Net Cash / Leverage $1.31 Book/Sh · -88.8% ROE $1.4M Net Debt (1.27x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KTTA (5) vs BFRI (4)
Institutional Metric KTTA BFRI Criterion Row Edge
Market Capitalization
Scale
$17.7M $10.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 13.0x Lower Multiple BFRI
Forward P/E Ratio
Valuation
N/M 13.0x Lower Multiple BFRI
Revenue Growth (YoY)
Growth
+1498.1% +29.8% Higher Growth KTTA
Operating Margin (TTM)
Profitability
0.0% -12.6% Higher Margin KTTA
Net Profit Margin
Profitability
0.0% -12.7% Higher Margin KTTA
Return on Equity (ROE)
Capital Efficiency
-88.8% -988.4% Higher ROE KTTA
52-Week Range Position
Momentum
11% ($0–$2) 0% ($1–$2) Stronger Trend KTTA
Beta / 30D Volatility
Risk Regime
0.68β · 185% Vol 1.84β · 125% Vol Lower Realized Risk BFRI
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 44.0 / 100 (HOLD) Higher Composite BFRI
Trailing 12M Revenue (USD)
Operating Scale
$486,559 $48M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-0.5% 79.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 36.3x EV/Rev N/M PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$18M ($1.31 Book/Sh · -88.8% ROE) -$9.3M ($1.4M Net Debt (1.27x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KTTA +39.66 pp
KTTA: +7.52% · BFRI: -32.14%
3M Horizon KTTA +58.49 pp
KTTA: -5.21% · BFRI: -63.7%
6M Horizon KTTA +2.76 pp
KTTA: -31.59% · BFRI: -34.35%
1Y Horizon KTTA +35.08 pp
KTTA: +0.59% · BFRI: -34.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period KTTA Revenue BFRI Revenue KTTA Op. Margin BFRI Op. Margin Margin Leader
FY2020 N/A $20M N/A -51.0% BFRI
FY2021 $0M $20M -29925.7% -104.6% BFRI
FY2022 $0M $30M -2587.3% -64.8% BFRI
FY2023 N/A $30M N/A -66.6% BFRI
FY2024 N/A $40M N/A -46.1% BFRI
FY2025 N/A $40M N/A -27.2% BFRI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KTTA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BFRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BFRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KTTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $17.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BFRI Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $10.2M market capitalization and -12.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KTTA vs BFRI Key Questions & Quantitative Answers

As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over Biofrontera Inc. (BFRI) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas BFRI carries 44.0/100 (HOLD) at $0.53 (13.0x Forward P/E, -12.6% operating margin). Composite vs. Pillar Nuance: While BFRI currently prints a higher short-term Unified Composite Score (44.0/100 HOLD vs. KTTA 42.1/100 HOLD), KTTA captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -12.6% operating margin) and revenue trajectory (+1498.1% vs. +29.8% YoY). Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile BFRI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KTTA leads the Growth & Scale pillar: KTTA posts +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin), compared with BFRI at +29.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (79.6% gross margin, -12.6% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), KTTA cumulative revenue shifted N/A while BFRI shifted +100.0%. In operating R&D and SG&A reinvestment, KTTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BFRI.

BFRI screens cheaper on headline valuation multiples. KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin), whereas BFRI trades at 13.0x Forward P/E, 13.0x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (-19.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KTTA (-88.8% ROE) versus BFRI (-988.4% ROE) capital efficiency.

In options market volatility and institutional positioning, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk). By comparison, BFRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 125% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.